arrow
R

Rachel A. Freedman

dana-farber brigham cancer center
H指数:41
被引数:7,426

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Research Letter: Frailty Within a Cohort of Older Adults With Breast Cancer: Groundwork for Future Geriatric-Specific Outcomes Data

研究快报:乳腺癌老年患者队列中的虚弱问题:未来老年特异性结局数据的基础工作

2026-06-030
PRE
Digitally engaging participants in cancer clinical trials: Design and pilot of the Alliance Participant Engagement Portal (PEP)

数字化参与癌症临床试验:联盟参与者参与门户(PEP)的设计与试点

2026-05-230
PRE
The LIFT UP study: feasibility of systematically identifying and addressing resource needs in those with metastatic breast cancer

LIFT UP研究:系统识别并应对转移性乳腺癌患者资源需求的可行性

2026-04-070
PRE
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA

检测细胞游离DNA中酪氨酸激酶抑制剂异质性耐药机制

2025-09-090
OAAI
Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trial

评估高风险、三阴性乳腺癌患者在新辅助治疗后存在残留病灶的疾病结局中的种族差异:ECOG-ACRIN 1131临床试验的事后分析

2025-08-040
PRE
Preliminary experience supporting older adults with breast cancer: Successes, challenges, and next steps for a program embedded in a breast oncology center

初步经验支持患有乳腺癌的老年患者:在乳腺癌肿瘤中心嵌入项目的成功、挑战及下一步计划

2025-06-010
PRE
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022

Neratinib和ado-曲妥珠单抗emtansine用于预处理和未治疗的人表皮生长因子受体2 (HER2) 阳性乳腺癌脑转移: 转化乳腺癌研究联盟试验022

2024-11-011
OAAI